Purpose: To determine the antitumor activity and toxicity of paclitaxel administered as a three-hour infusion and to estimate the incidence of hypersensitivity reactions using a shortcourse prophylaxis regimen in patients with advanced gastric cancer.
Introduction
Gastric cancer remains a major health problem worldwide. In Japan, this neoplasm represents the most frequently diagnosed cancer in women and the second in men. Approximately 50,000 deaths in Japan were observed in 1997 as a result of gastric cancer [1] . The two-year survival rate for patients with metastatic gastric cancer is only 10% [2] , despite treatment with different anticancer agents. The main chemotherapeutic agent used for advanced gastric cancer for four decades, 5-fluorouracil (5-FU), produces a single-agent response rate (RR) of only 12% and median survival time (MST) was seven months [2] . In a recent randomized phase III trial of European Organization for Research and Treatment of Cancer, the MSTs were approximately seven months with ELF (etoposide, leucovorin and bolus 5-FU), FUP (infusional 5-FU plus cisplatin) and FAMTX (5-FU, doxorubicin and methotrexate), respectively [3] . The other combination therapy of irinotecan and cisplatin showed a RR of 48% and a MST of approximately nine months [4] . The therapeutic impact of these results on survival has been modest. New anticancer agents are therefore needed to improve the prognosis of patients with metastatic gastric cancer.
Paclitaxel is a chemotherapeutic agent derived from the bark of the Pacific Yew tree, Ta.xus brevifolia, which acts as an antimitotic agent by binding to microtubules, and has demonstrated substantial clinical and preclinical activity [5] [6] [7] . Clinical trials have established that paclitaxel is one of the most active drugs available for breast, ovarian and non-small-cell lung cancer (NSCLC). In addition, paclitaxel has demonstrated substantial activity in vitro against MKN-28 and MKN-45 gastric carcinoma cell lines [8] . A recent early phase II trial against gastric cancer with a limited number of patients demonstrated promising activity, with a RR of 20%, in 3 of 15 patients [9] .
In the past, Paclitaxel has often been given as a 24-hour infusion, a schedule that was selected to reduce the high incidence and severity of hypersensitivity reactions recorded in the earliest clinical trials. A recently reported trial in ovarian cancer, however, showed that the three-hour schedule has similar activity and less toxicity than the 24-hour schedule [10] . The incidence of severe hypersensitivity reactions was low and did not increase with the three-hour infusion with premedication. Furthermore, preliminary results from a large multicenter trial of the three-hour schedule show comparable efficacy to the 24-hour schedule in patients with breast cancer and NSCLC [11, 12] . In a previous phase I trial of paclitaxel given by three-hour infusion in Japan, it was determined that the maximum tolerable dose was 240 mg/m 2 and the dose recommended for phase II trials was 210 mg/m 2 [13] .
A standard premedication regimen used to avoid paclitaxel-associated hypersensitivity reactions has included 20 mg oral dexamethasone administered 12 and 6 hours before paclitaxel as well as both H, and H 2 histamine antagonists also administered prior to treatment with paclitaxel [14] . Bookman et al. [15] has successfully treated patients with a short-course intravenous prophylaxis regimen (diphenhydramine 50 mg, cimetidine 300 mg or ranitidine 50 mg, and dexamethasone 5 to 20 mg) given 30 min prior to paclitaxel. The overall incidence of hypersensitivity reactions was 4.6%, which compares favorably to published data with a conventional oral prophylaxis regimen. These results showed that the short-course prophylaxis regimen offers a safe and convenient alternative for prevention of hypersensitivity reactions and facilitates paclitaxel administration in an outpatient setting.
The objectives of this phase II trial were to determine the antitumor activity and toxicity of paclitaxel 210 mg/m 2 administered as a three-hour infusion with short-course premedication to patients with advanced gastric cancer.
Before being registered for the study, all patients underwent a physical examination, with documentation of measurable or evaluable disease; complete blood cell (CBC) count with differential serum chemistry analysis, chest X-ray, electrocardiogram and computed tomographic (CT) scan of the abdomen.
Treatment plan
Patients were premedicated with dexamethasone 20 mg and ranitidine 50 mg intravenously and were given diphenhydramine 50 mg orally 30 min before paclitaxel to prevent hypersensitivity reactions. Paclitaxel was then administered at a dose of 210 mg/m 2 by infusion over three hours in the outpatient setting. Paclitaxel was diluted in 500 ml 5% glucose or normal saline no more than 30 min before use. Treatment cycles were repeated every three weeks, with response assessment every three weeks. Subsequent cycles of paclitaxel were not administered until the leukocyte count was greater than 4,000/ul, the neutrophil count = 2,000/ul, and the platelet count greater than 100,000/ul.
The dose was modified for each patient according to a nomogram, which was based on hematologic or non-hematologic toxicity. If the lowest leukocyte count was = 1,000/ul or platelet count = 25,000/ul, dose level was reduced to 180 mg/m 2 (step 1) or 150 mg/m 2 (step 2). If the day 21 leukocyte count was = 4,000/ul and neutrophil count was = 2,000/ul or the platelet count = 100,000/ul, further treatment was delayed one or two weeks until recovery. JCOG grade 3 or 4 nonhematologic toxicity could be managed by symptomatic treatment and one step dose reduction of paclitaxel for subsequent cycles. Recombinant granulocyte colony-stimulating factor was subcutaneously injected if patients had a leukocyte count < 1,000/ul or a neutrophil count <500/ul, but was not routinely used. Clinically significant hypersensitivity reactions required immediate discontinuation of the paclitaxel infusion and appropriate supportive measures.
Response and toxicity criteria
Response of measurable and evaluable sites of disease was assessed according to WHO criteria [17] Toxicities were assessed using the toxicity criteria of JCOG [16] . While on study, all patients were evaluated weekly for symptoms of toxicity. CBC counts including differential, liver function tests, urea nitrogen, creatinine, electrolytes and urinalysis were performed weekly. Patients were assessed for measurements of tumor size every three weeks. The observed responses were confirmed by an independent review committee.
Patients and methods

Patient eligibility
The study was open to patients with histologically confirmed gastric cancer who had previously received at most one chemotherapy regimen (either as adjuvant therapy or for metastatic disease) and who had measurable disease. There was no limitation for prior radiotherapy other than a four-week interval from completion until study entry.
Patients had to be between 20 to 75 years of age, with an Eastern Cooperative Group (ECOG) performance status of 0-2 and have adequate baseline bone marrow function (neutrophil count = 2,000/ul and platelet = 100,000/ul), hepatic function (serum bilirubin level 1.5 mg/dl or less, and serum GOT and GPT = 2 times the upper limit of the normal range), renal function (blood urea nitrogen level 25 mg/dl or less and serum creatinine level 1.5 mg/dl or less) and a life expectancy of at least eight weeks, to be eligible for this study.
Patients were ineligible if they had symptomatic brain metastasis, or preexisting neuropathy grade 2 or greater after the Japan Clinical Oncology Study Group (JCOG) [17] . This study was approved by the institutional review boards of each participating hospital. All patients gave written informed consent.
Statistical methods
The sample size of this study was calculated based on a target activity level of 20% and a minimum activity level of 10%, with a error of 0.05 and (3 error of 0.2. Therefore, the required number of patients was 60.
Overall survival was measured from the start of paclitaxel treatment to the date of death. The Kaplan-Meier method was used to estimate the overall survival curves. Survival time was censored al the close out date if the patients were alive.
Results
Patient characteristics
Sixty patients were entered into this study between May 30, 1997 and June 10, 1999 at five centers in Japan. All 60 patients were evaluated for response and toxicity in the intent to treat analysis. Patient baseline characteristics are listed in Table 1 . The majority of patients were of courses was three (range 1 to 11) and the total number of cycles was 203. The median dose intensity was 68.4 mg/m 2 /week of paclitaxel.
Response and survival
There was no CR. Fourteen patients achieved a PR, for an overall RR of 23% (95% CI: 13%-36%). One patient was not definitively evaluated for response because subsequent treatments had been initiated before the confirmation of NC, and another patient had no measurable lesion. The median response duration was 152 days (range 64 to 358 days) and the median time to response was 30 days (range 16-59 days). Complete regression of liver metastases was observed in one patient who had liver, lung and lymph node metastases. The RRs to paclitaxel in patients with diffuse-type and intestinaltype adenocarcinoma were 29% (9 of 31) and 17% (5 of 29), respectively. Paclitaxel demonstrated a RR of 26% (7 of 26) in patients who had received prior chemotherapy and 21% (6 of 28) in those patients with no prior chemotherapy. The survival by treatment arm is shown in Figure 1 . The MST was 340 days (95% CI: 306-389 days, range 62 to 764 days). The one-year survival rate was 43%. The MST in patients with previously treatment was 319 days and that in chemotherapy-naive patients was 348 days.
Toxicities
All patients showed normal leukocyte, neutrophil and platelet counts at the start of paclitaxel administration as required by the protocol of this study. Twenty-six of sixty patients (43%) had anemia at the baseline. Hematologic toxicities are summarized in Table 3 . Neutropenia was the most common and serious toxicity, with 22 of 60 patients (37%) experiencing grade 3 or 4 neutropenia, of which four patients (7%) developed febrile neutropenia. There were no episodes of any grade thrombocytopenia.
Non-hematologic toxicities are listed in Table 4 . Peripheral neuropathy was typically described as numbness, tingling and burning that started in the fingers and toes and moved up to the legs and hands in a stocking and glove distribution. Grade 3 neuropathy occurred in one patient. Neuropathy tended to be more severe following repeated drug administrations, while reversibility was a slow process. Myalgias and arthralgias did not increase in incidence with successive cycles. Hypersensitivity reactions were recorded in only 9 patients (15%) and were all grade 1. Grade 3 of transient hypertension was observed in two patients with essential hypertension. Both of these patients recovered immediately after medication. Two patients developed grade 1 hypotension without other allergic reactions during the paclitaxel infusion and did not require interruption of the infusion. No treatment-related deaths were observed during this study.
Discussion
The present investigation was undertaken to assess the activity and tolerability of paclitaxel administered once every three weeks at a dose of 210 mg/m 2 by a threehour infusion in metastatic gastric cancer. The 23% RR documented in our study can be considered along with the results described by other investigators who gave paclitaxel by three-hour infusion to a small number of patients. Ohtsu et al. [18] reported a RR of 20% when using paclitaxel by a three-hour infusion in 15 previously treated patients. Cascinu et al. [19] showed a 22.2% (8 of 36) in pretreated advanced gastric cancer patients with a three-hour infusion at a dose of 225 mg/m 2 . Einzig et al. [20] , however, reported a RR of only 4.5% (1 of 22) with a 24-hour infusion at 250 mg/m 2 in patients with adenocarcinomas of the upper gastrointestinal tract. Ajani et al. [21] showed an overall RR of 17% (5 of 30) for gastric adenocarcinoma, 8% (1 of 13) RR with a threehour infusion first in 13 patients and subsequently 23% (4 of 17) with a 24-hour infusion in 17 patients. There are limitations to comparing the different studies, however, as the extent of prior therapy differs. Nevertheless, in our experience, the administration of paclitaxel by a threehour infusion was associated with favorable therapeutic results. In this study, 26 patients had been previously treated with regimens including 5-FU, cisplatin, irinotecan and methotrexate. The RR with paclitaxel in those patients was 26%. Responses were evenly distributed, regardless of prior chemotherapy. These data are in agreement with preliminary results described by Ohtsu [18] and show no cross-resistance to other active agents gastric cancer. The MST in this phase II trial of paclitaxel was 11 months which was promising and comparable or superior to that typically seen for combination therapy such as cisplatin and irinotecan [4] . The MST in patients who failed to respond to previous therapy was 10 months and these are likely to show a clinical benefit from paclitaxel therapy. This will require quantification in a randomized phase III study.
The median dose intensity was 68.4 mg/m 2 /week and most of the patients received paclitaxel according to the stipulated dose and schedule of 210 mg/m 2 every three weeks. The most common adverse reaction was grade 3 or 4 neutropenia, which developed in 37% of patients in the study. However, neutropenic fever developed in only four patients due to the short duration of myelosuppression. The incidence of severe neutropenia was similar to that reported when three-hour infusions of paclitaxel at a dose of 210 mg/m 2 were given to patients with breast cancer, ovarian cancer or NSCLC [22] [23] [24] . Other grade 3 or 4 non-hematologic toxicities, apart from alopecia, were myalgia (3%) and peripheral neuropathy (2%). These toxicities have been reported to be more common when paclitaxel is given over three hours. The incidence of peripheral neuropathy was cumulative, this toxicity disappeared in 55% of patients after cessation of therapy.
Standard premedication has included 20 mg oral dexamethasone administered 12 and 6 hours prior to treatment with paclitaxel. However, this regimen requires increased patient vigilance in order to avoid treatment delay in the event of missed dosing and also exposes the patient to multiple high doses of corticosteroid. In this study, we used a short-course prophylaxis regimen. Hypersensitivity reactions such as bronchospasm, stridor, urticaria and flushing were not recorded in this study. This incidence of hypersensitivity is similar to many previous reports with the standard prophylaxis regimen [10, 22] .
In conclusion, our study showed that paclitaxel is a safe, well-tolerated and active agent when administered by three-hour infusion in patients with advanced gastric cancer, with or without previous chemotherapy. The short-course premedication regimen used (dexamethasone, diphenhydramine and ranitidine, administered approximately 30 min prior to the administration of paclitaxel) offers a safe and convenient alternative which facilitates paclitaxel administration in the outpatient setting. Furthermore, this study suggests a lack of crossresistance between paclitaxel and other agents active against gastric cancer. We believe further development of this drug in combination therapy is warranted.
